search icon
rlay-img

Relay Therapeutics Inc, Common Stock

RLAY

NMQ

$3.08

+$0.13

(4.41%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$487.76M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
796.10K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.66
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.77 L
$10.72 H
$3.08

About Relay Therapeutics Inc, Common Stock

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRLAYSectorS&P500
1-Week Return8.26%0.71%0.79%
1-Month Return-0.65%-5.6%6.04%
3-Month Return-9.68%-11.72%-1.11%
6-Month Return-34.47%-10.81%-2.39%
1-Year Return-50.24%-7.12%11.69%
3-Year Return-81.08%-0.57%42.29%
5-Year Return-91.21%27.64%93.12%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue82.65M3.03M1.38M25.55M10.01M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.66,"profit":true},{"date":"2022-12-31","value":1.67,"profit":true},{"date":"2023-12-31","value":30.91,"profit":true},{"date":"2024-12-31","value":12.11,"profit":true}]
Cost of Revenue3.55M3.92M4.13M5.27M5.46M[{"date":"2020-12-31","value":64.95,"profit":true},{"date":"2021-12-31","value":71.83,"profit":true},{"date":"2022-12-31","value":75.59,"profit":true},{"date":"2023-12-31","value":96.43,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit79.11M(896.00K)(2.75M)20.28M4.54M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1.13,"profit":false},{"date":"2022-12-31","value":-3.48,"profit":false},{"date":"2023-12-31","value":25.63,"profit":true},{"date":"2024-12-31","value":5.74,"profit":true}]
Gross Margin95.71%(29.58%)(199.06%)79.37%45.40%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-30.91,"profit":false},{"date":"2022-12-31","value":-207.99,"profit":false},{"date":"2023-12-31","value":82.94,"profit":true},{"date":"2024-12-31","value":47.43,"profit":true}]
Operating Expenses138.45M230.04M312.33M398.55M382.48M[{"date":"2020-12-31","value":34.74,"profit":true},{"date":"2021-12-31","value":57.72,"profit":true},{"date":"2022-12-31","value":78.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":95.97,"profit":true}]
Operating Income(55.80M)(364.70M)(299.27M)(373.00M)(372.47M)[{"date":"2020-12-31","value":-5579600000,"profit":false},{"date":"2021-12-31","value":-36469800000,"profit":false},{"date":"2022-12-31","value":-29927500000,"profit":false},{"date":"2023-12-31","value":-37300000000,"profit":false},{"date":"2024-12-31","value":-37246800000,"profit":false}]
Total Non-Operating Income/Expense6.78M1.66M17.55M62.07M69.51M[{"date":"2020-12-31","value":9.76,"profit":true},{"date":"2021-12-31","value":2.38,"profit":true},{"date":"2022-12-31","value":25.25,"profit":true},{"date":"2023-12-31","value":89.3,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(52.41M)(363.87M)(290.51M)(341.97M)(337.71M)[{"date":"2020-12-31","value":-5241200000,"profit":false},{"date":"2021-12-31","value":-36387200000,"profit":false},{"date":"2022-12-31","value":-29050900000,"profit":false},{"date":"2023-12-31","value":-34197300000,"profit":false},{"date":"2024-12-31","value":-33770800000,"profit":false}]
Income Taxes(3.40M)132.94M(36.25M)(37.47M)(337.71M)[{"date":"2020-12-31","value":-2.56,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-27.27,"profit":false},{"date":"2023-12-31","value":-28.18,"profit":false},{"date":"2024-12-31","value":-254.04,"profit":false}]
Income After Taxes(49.01M)(496.81M)(254.26M)(304.51M)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(52.41M)(363.87M)(290.51M)(341.97M)(337.71M)[{"date":"2020-12-31","value":-5241200000,"profit":false},{"date":"2021-12-31","value":-36387200000,"profit":false},{"date":"2022-12-31","value":-29050900000,"profit":false},{"date":"2023-12-31","value":-34197300000,"profit":false},{"date":"2024-12-31","value":-33770800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(49.01M)(496.81M)(254.26M)(341.97M)(337.71M)[{"date":"2020-12-31","value":-4901200000,"profit":false},{"date":"2021-12-31","value":-49680800000,"profit":false},{"date":"2022-12-31","value":-25425900000,"profit":false},{"date":"2023-12-31","value":-34197300000,"profit":false},{"date":"2024-12-31","value":-33770800000,"profit":false}]
EPS (Diluted)(6.26)(3.85)(2.60)(2.80)(2.39)[{"date":"2020-12-31","value":-626,"profit":false},{"date":"2021-12-31","value":-385,"profit":false},{"date":"2022-12-31","value":-260,"profit":false},{"date":"2023-12-31","value":-280,"profit":false},{"date":"2024-12-31","value":-239,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RLAY
Cash Ratio 2.52
Current Ratio 19.96

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RLAY
ROA (LTM) -28.82%
ROE (LTM) -45.46%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RLAY
Debt Ratio Lower is generally better. Negative is bad. 0.10
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.90

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RLAY
Trailing PE NM
Forward PE NM
P/S (TTM) 68.77
P/B 0.73
Price/FCF NM
EV/R 18.17
EV/Ebitda NM

FAQs

What is Relay Therapeutics Inc share price today?

Relay Therapeutics Inc (RLAY) share price today is $3.08

Can Indians buy Relay Therapeutics Inc shares?

Yes, Indians can buy shares of Relay Therapeutics Inc (RLAY) on Vested. To buy Relay Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RLAY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Relay Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Relay Therapeutics Inc (RLAY) via the Vested app. You can start investing in Relay Therapeutics Inc (RLAY) with a minimum investment of $1.

How to invest in Relay Therapeutics Inc shares from India?

You can invest in shares of Relay Therapeutics Inc (RLAY) via Vested in three simple steps:

  • Click on Sign Up or Invest in RLAY stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Relay Therapeutics Inc shares
What is Relay Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Relay Therapeutics Inc (RLAY) is $10.72. The 52-week low price of Relay Therapeutics Inc (RLAY) is $1.77.

What is Relay Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Relay Therapeutics Inc (RLAY) is 0.73

What is the Market Cap of Relay Therapeutics Inc?

The market capitalization of Relay Therapeutics Inc (RLAY) is $487.76M

What is Relay Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Relay Therapeutics Inc is RLAY

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top